ChondroCelect
·
- Prescription status not stated
- Muscles, joints and bones
- Active substance
- Characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
- Used in
- Muscles, joints and bones
- Made by
- TiGenix N.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Repair of single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults. Concomitant asymptomatic cartilage lesions (ICRS grade I or II) might be present. Demonstration of efficacy is based on a randomised controlled trial evaluating the efficacy of Chondrocelect in patients with lesions between 1 and 5 cm².
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
NetherlandsNo exact match for this strength and form
Details
| Made by | TiGenix N.V. |
|---|---|
| Active substance | Characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins |
| Used in | Muscles, joints and bones |
| Classification | M09AX02 · Muscles, joints and bones |
| Authorised on | 2009-10-05 |
| Last updated by the regulator | 2017-01-12 |
| EMA product number | EMEA/H/C/000878 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).